Isoniazid

Generic Name: Isoniazid

Brand Names: Isonarif, Isotamine, Isotamine B, Rifamate, Rifater

Drug Type: Small Molecule

Chemical Formula: C_₆H_₇N_₃O

CAS Number: 54-85-3

Unique Ingredient Identifier: V83O1VOZ8L

Background: Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Indication: Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.

Associated Conditions: Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis

Clinical Trials

Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

Phase 1

Completed

Conditions: HIV Infected Population With Latent Tuberculosis

Interventions: Drug: rifapentene (RPT)
Drug: darunavir/cobicistat (DRV/c)
Drug: Isoniazid (INH)
Dietary Supplement: Pyridoxine

First Posted Date: 2016-05-13

Last Posted Date: 2022-04-18

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 37

Registration Number: NCT02771249

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Correlate of Risk Targeted Intervention Study

Phase 2

Conditions: Tuberculosis

Interventions: Drug: Isoniazid
Drug: Rifapentine

First Posted Date: 2016-04-12

Last Posted Date: 2018-12-24

Lead Sponsor: University of Cape Town

Target Recruit Count: 2927

Registration Number: NCT02735590

Locations: 🇿🇦
Stellenbosch Immunology Research Group, Cape Town, Western Cape, South Africa
🇿🇦
Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, KwaZulu-Natal, South Africa
🇿🇦
South African Tuberculosis Vaccine Initiative (SATVI), Worcester, Western Cape, South Africa

and more 1 locations

Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: INH 208 U
Drug: INH 139 U
Drug: LIS 18 U
Drug: INH 69 U (low)
Drug: INH 69 U (high)

First Posted Date: 2016-03-23

Last Posted Date: 2016-03-23

Lead Sponsor: Dance Biopharm Inc.

Target Recruit Count: 24

Registration Number: NCT02716610

Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifapentine (RPT)
Drug: Isoniazid (INH)
Dietary Supplement: Pyridoxine (vitamin B6)

First Posted Date: 2016-01-08

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT02651259

Locations: 🇿🇼
Harare Family Care CRS, Harare, Zimbabwe
🇲🇼
Malawi CRS, Lilongwe, Central Malawi, Malawi
🇭🇹
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti

and more 2 locations

Infant TB Infection Prevention Study

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Isoniazid

First Posted Date: 2015-11-24

Last Posted Date: 2023-04-28

Lead Sponsor: University of Washington

Target Recruit Count: 300

Registration Number: NCT02613169

Locations: 🇰🇪
Kisumu County Hospital, Kisumu, Kenya

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

Phase 3

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Ethambutol
Drug: Pyrazinamide

First Posted Date: 2015-10-21

Last Posted Date: 2023-04-27

Lead Sponsor: St George's, University of London

Target Recruit Count: 672

Registration Number: NCT02581527

Locations: 🇺🇬
Epicentre, Mbarara, Uganda
🇵🇪
Hospital Nacional Dos de Mayo, Lima, Peru
🇳🇵
GENETUP, National Anti-TB Association, Kathmandu, Nepal

and more 3 locations

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Phase 3

Conditions: Tuberculosis

Interventions: Drug: Rifampin
Drug: Rifapentine
Drug: Isoniazid
Drug: Moxifloxacin
Drug: Pyrazinamide
Drug: Ethambutol
Dietary Supplement: Pyridoxine

First Posted Date: 2015-09-30

Last Posted Date: 2017-03-01

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 60

Registration Number: NCT02563327

Locations: 🇺🇬
Mulago Hospital, Kampala, Uganda

Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia

Not Applicable

Completed

Conditions: Motor Activity
Body Weight Changes
Pulmonary Tuberculosis

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Ethambutol
Dietary Supplement: Fermented soybean

First Posted Date: 2015-09-18

Last Posted Date: 2022-06-21

Lead Sponsor: University of Giessen

Target Recruit Count: 147

Registration Number: NCT02554318

The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis

Phase 4

Conditions: Tuberculosis, Spinal

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Ethambutol
Drug: Pyrazinamide

First Posted Date: 2015-06-23

Last Posted Date: 2015-06-23

Lead Sponsor: Beijing Chest Hospital

Target Recruit Count: 400

Registration Number: NCT02477852

Locations: 🇨🇳
Beijing chest hospital, Beijing, Beijing, China

Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: HRZE
Drug: Isoniazid with HUEXC030 and RZE

First Posted Date: 2015-06-10

Last Posted Date: 2022-06-15

Lead Sponsor: Orient Pharma Co., Ltd.

Target Recruit Count: 557

Registration Number: NCT02467608

Locations: 🇨🇳
Cheng Hsin General Hospital, Taipei, Taiwan
🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan
🇨🇳
Chang Gung Memorial Hospital, ChiaYi, Chiayi City, Taiwan

and more 15 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy